|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Departamento de Emergencia (Dr. G. J. Rodrigo), Hospital Central de las FF.AA.; and Unidad de Cuidado Intensivo (Dr. C. Rodrigo), Asociación Española 1a de Socorros Mutuos, Montevideo, Uruguay.
Correspondence to: Gustavo J. Rodrigo, MD, Departamento de Emergencia, Hospital Central de las FF.AA., Av. 8 de Octubre 3020, Montevideo 11600, Uruguay; e-mail: gurodrig{at}adinet.com.uy
| Abstract |
|---|
|
|
|---|
Subjects and methods: Four
hundred three patients (with peak expiratory flow [PEF] or
FEV1 of < 50% of predicted value) with acute
exacerbations of asthma were enrolled in the trial using a prospective
cohort study. Asthma attacks were classified as an ROAA (< 6 h of
symptoms) or an SOAA (
6 h). All patients were treated with
albuterol, four puffs at 10-min intervals (100 µg per actuation),
delivered by metered-dose inhaler with a spacer device during 3
h.
Results: On the basis of previously determined criteria, 11.3% of patients were classified as having a ROAA. Male patients comprised 53.6% of the ROAA group (p = 0.03). In ROAA patients, the exacerbation was less likely to be attributed to respiratory tract infection (p = 0.001) and more likely to have no identifiable cause (p = 0.0001). Also, ROAA patients had lower pulmonary function (FEV1) at presentation (mean difference, - 0.13; 95% confidence interval [CI], - 0.22 to - 0.04 L; p = 0.04) than SOAA patients. At the end of treatment, ROAA patients had an overall 48.0 L/min (95% CI, 14.1 to 81.8 L/min) greater improvement in PEF and a 0.31 L (95% CI, 0.08 to 0.54 L) greater improvement in FEV1 than SOAA patients. Also, ROAA patients presented with less accessory muscle use (p < 0.05) and higher oxygen saturation (p = 0.005). Finally, SOAA patients showed an increased incidence of hospital admission (relative risk, 3.89; 95% CI, 1.01 to 15.0).
Conclusions: Data from this study support the notion that ROAAs constitute a distinct but uncommon acute asthma ED presentation, with a predominance of male patients. Upper respiratory tract infection was not believed to be a significant trigger factor in these patients, and ROAA patients had rapid deterioration of their conditions followed by a more rapid response to treatment and a lower hospital admission rate than SOAA patients. Thus, we have identified a subgroup of patients who appear to have common characteristics with patients with sudden-onset near-fatal/fatal asthma.
Key Words: acute severe asthma near-fatal asthma sudden-onset asthma
| Introduction |
|---|
|
|
|---|
Most studies3 5 6 11 12 13 14 15 16 17 18 19 20 21 22 concerning the speed of onset of acute severe asthma include retrospective reports of patients free of asthma symptoms who develop acute severe asthma and respiratory arrest or failure (sudden-onset asthma attacks/sudden-asphyxic asthma/near-fatal asthma), sometimes with fatal consequences (sudden-onset fatal asthma). Since larger clinical trials that analyze the frequency and main characteristics of this type of patient at emergency department (ED) presentation are uncommon, we designed a prospective trial to study the rapidity of onset in adults with acute severe asthma attacks. The main objectives of this study were as follows: (1) to determine the frequency of ROAAs and SOAAs in adult patients with acute, severe asthma who presented to an ED; (2) to establish whether ROAA patients differ from SOAA patients in terms of clinical and spirometric characteristics; and (3) to determine whether ROAA patients differ from SOAA patients in terms of response to treatment.
| Materials and Methods |
|---|
|
|
|---|
Protocol
After initial assessment, all patients were treated with
albuterol, four puffs at 10-min intervals (100 µg per actuation),
delivered by a metered-dose inhaler and a spacer device (Volumatic;
Allen & Hansburys; Greenford, UK). Each dose was followed by a
deep inhalation from the spacer device. The protocol involved 3 h
of this treatment (1,200 µg of albuterol every 30 min). After this
time, all patients with a poor response received hydrocortisone, 500 mg
IV. The protocol included the administration of
O2 if arterial oxygen saturation
(SaO2) decreased to < 92%.
Aminophylline was excluded in all patients. The patients were
independently assessed and treated by physicians, all of whom were
unaware of the previous duration of attack and pulmonary function. All
subjects completed the protocol. The decision to discharge or admit a
patient to the hospital was made at the end of protocol by senior ED
staff without knowledge of previous patient group allocation. Patients
were discharged from the ED according to the following criteria: if
accessory muscle use had abated, if wheezing was judged to be minimal
or completely resolved, if dyspnea abated, and if
FEV1 or PEF was > 60% of predicted. The
physicians prescribed oral prednisone, 60 mg for 7 days, for all
discharged patients, or IV steroids for those who were admitted.
Measurements
Patients or relatives were asked about relevant aspects of
asthma history and outpatient therapy. To determine the duration of
onset of present attack, patients were asked to indicate the onset of
wheeze, cough, shortness of breath, or some combination of these
symptoms; also, a decline in the PEF, if available, was noted. When
possible, the patients relatives were asked to confirm information
regarding the duration of symptoms before ED presentation. Severe
asthma attacks were classified in accord with Kolbe et al5
as an ROAA (< 6 h) or an SOAA (
6 h). That definition was selected
to distinguish from previous definitions of sudden-onset asthma attacks
(respiratory arrest or failure within 11/2 h,8
or
3 h,3
after the onset of attack). The following
variables were measured in each patient immediately before starting
treatment, and at 30, 60, 90, 120, 150, and 180 min:
FEV1, PEF, respiratory rate, heart rate,
accessory muscle use, dyspnea, wheezing, and
SaO2. PEF was measured with a
mini-Wright peak flowmeter (Clement Clarke; Harlow, UK). The highest of
three values was recorded. FEV1 was measured
using a Vitalograph Compact spirometer (Vitalograph; Maids Moreton
House; Buckingham, UK). Three successive maximal expiratory curves were
recorded at each assessment, and the highest value was selected,
according to the criteria of the American Thoracic
Society.24
Heart rate was measured from continuous ECG.
SaO2 was measured with a finger
oximeter (N-180 Pulse Oximeter; Nellcor; Hayward, CA). Accessory-muscle
use was defined as visible retraction of the sternocleidomastoid
muscles.25
Dyspnea was defined as the patients own
assessment of breathlessness. Wheezing was defined as musical or
whistling breath sounds heard with a stethoscope during expiration.
These clinical factors were graded in a scale from 0 to 3 in which 0
denoted absent, 1 denoted mild, 2 denoted moderate, and 3 denoted
severe. Finally, a score for severity was produced for each patient
using the National Asthma Education and Prevention Program (range 1 to
4; mild intermittent to severe persistent).26
Statistical Methods
All data were analyzed with an SPSS 10.0 for Windows software
package (SPSS; Chicago, IL). Changes in FEV1 and
PEF were evaluated using repeated-measures analysis of variance
(ANOVA), with one between-subject factor (rapid-slow) and one
within-subject factor (time). One-way repeated-measures ANOVA was used
to compare baseline values for each variable, after assessing both
normality of distributions and homoscedasticity. When the F
value indicated significant differences among group means, post
hoc pairwise multiple comparisons were performed using the
Newman-Keuls test. Baseline data of the two treatments were compared by
t test for normally distributed independent samples or the
Mann-Whitney U test for nonnormally distributed continuous
variables.
2 with Yates correction or
Fishers Exact Test was used for categorical variables. Clinical
factors graded on a scale of 0 to 3 were reported as medians and
interquartile ranges. A p value of < 0.05 using a two-tailed test was
taken as being of significance for all statistical tests. Mean
values ± SD were calculated for continuous variables. Ninety-five
percent confidence intervals (CIs) and relative risks were calculated
with standard formulas.27
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
These findings were in concurrence with Kolbe and
coworkers,5
who performed a cross-sectional study on 316
patients aged 15 to 49 years who were admitted to the hospital with
acute, severe asthma and found that only 8.5% were classified as
having rapid-onset asthma (< 6-h duration), again with a
preponderance of male patients. Patients were interviewed within 24 to
48 h of hospital admission to determine the duration of attack.
Similarly, Woodruff et al,6
in a retrospective cohort
study of 225 patients with severe (PEF of
40% of predicted) acute
asthma (18 to 64 years old) who were seen in an ED, reported 17% of
patients as having "sudden onset" asthma (
3 h). These patients
with sudden-onset asthma were less likely to have reported an upper
respiratory tract infection and, as in our study, were more likely to
have no unidentifiable trigger. No PEF baseline data were included.
Recently, Barr et al,28
in a large, multicenter,
prospective study of patients with severe, acute asthma (PEF < 50%),
found a rate of ROAA occurrence of 14%. ROAA patients were more likely
to be triggered by respiratory allergens, exercise, and psychosocial
stress, and less likely to be triggered by upper respiratory
infections. In addition, these patients demonstrate greater improvement
with therapy. Unlike our study, treatment of patients was managed at
the discretion of treating physicians.
ROAA occurrence rates differ widely among studies. Arnold and colleagues,2 in a prospective study of patients with acute asthma admitted to the hospital, estimated that in 46% of cases the speed of onset was < 24 h and in 13% of cases it was < 1 h. The duration of attack was determined from clinical history. This study also reported an association between age and duration of attack: rapid-onset attacks occurred more frequently in younger patients. Our study did not find a similar association with age.
Our trial sample presented the typical features of adult patients with severe asthma who presented for care to an ED without life-threatening exacerbations. On the contrary, most studies3 5 6 11 12 13 14 15 16 17 18 19 20 21 22 29 30 regarding the speed of onset of acute severe asthma include selected retrospective reports of patients free of asthma symptoms who develop acute severe asthma and respiratory arrest or failure (sudden-onset asthma attacks/sudden-asphyxic asthma/near-fatal asthma), sometimes with fatal consequences (sudden-onset fatal asthma). Wasserfallen et al3 studied 34 patients intubated for acute asthma and found that 29.4% of patients had "rapid decompensation." However, the duration of attack was established by "a history of extremely rapid deterioration, out of a clear blue sky" leading to intubation and mechanical ventilation within 3 h after the onset of the first symptoms. These authors concluded that sudden-onset asthma was more frequent in young men and was characterized by more severe acidosis and hypercapnia.
Likewise, Kallenbach et al31 studied 81 patients with acute severe asthma in whom mechanical ventilation was required, and concluded that a "hyperacute" attack duration (< 3 h from onset of attack to intubation) was associated with an increased risk of near fatality. Martin and coworkers29 examined 30 cases of near-fatal asthma attacks in children < 15 years old and found a low prevalence of rapid-onset attacks (17%). As in our study, the information was obtained from a standardized interview and questionnaire that was completed with subjects/parents.
The third objective of our study was to determine whether ROAA patients differ from SOAA patients in terms of response to treatment. In accord with previous work,30 our data suggest that 400 µg (four puffs) of albuterol at 10-min intervals delivered with a metered-dose inhaler and a spacer device is an effective treatment that produces a dose-related bronchodilator response in patients with acute severe asthma. However, we found two different therapeutic responses to treatment patterns: ROAA patients have rapid deterioration followed by a more rapid response to treatment and a lower hospital admission rate than SOAA patients. Similarly, other studies have found a positive correlation between the duration of attack and the duration of the required mechanical ventilation3 4 8 31 : SOAA patients required more-prolonged mechanical ventilation than that observed in ROAA patients.
| Conclusion |
|---|
|
|
|---|
| Footnotes |
|---|
Received for publication December 30, 1999. Accepted for publication May 31, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J M FitzGerald and P G Gibson Asthma exacerbations {middle dot} 4: Prevention. Thorax, November 1, 2006; 61(11): 992 - 999. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. James, J. G. Elliot, M. J. Abramson, and E. H. Walters Time to death, airway wall inflammation and remodelling in fatal asthma Eur. Respir. J., September 1, 2005; 26(3): 429 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
G J Rodrigo and C Rodrigo Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma Emerg. Med. J., June 1, 2005; 22(6): 404 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Maffei, E. W. van der Jagt, K. S. Powers, S. W. Standage, H. V. Connolly, W. G. Harmon, J. S. Sullivan, and J. S. Rubenstein Duration of Mechanical Ventilation in Life-Threatening Pediatric Asthma: Description of an Acute Asphyxial Subgroup Pediatrics, September 1, 2004; 114(3): 762 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Rodrigo and C. Rodrigo Triple Inhaled Drug Protocol for the Treatment of Acute Severe Asthma Chest, June 1, 2003; 123(6): 1908 - 1915. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Plaza, J. Serrano, C. Picado, and J. Sanchis Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma Eur. Respir. J., May 1, 2002; 19(5): 846 - 852. [Abstract] [Full Text] [PDF] |
||||
![]() |
Rapid-Onset Asthma Attacks Are Different Journal Watch Emergency Medicine, February 28, 2001; 2001(228): 1 - 1. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |